Importantly, in vitro-generated DCs from melanoma patients stimulated with TRIMEL induced a fivefold increase of IFN-γ release by a melanoma-specific cytotoxic T cell clone, compared to APCs stimulated with a non-HS-treated melanoma cell lysate [11], indicating the importance of the HS treatment in the capacity of TRIMEL to induce DCs with immunostimulatory properties. Here, IFNG is linked to melanoma.